Despite their efficacy in the treatment of non-small cell lung cancer (NSCLC), ALK TKIs have a broad toxicity profile including shortness of breath, gastrointestinal (GI) intolerance, anemia, elevated liver enzymes, and fatigue (5). The gene discussed is ALK; the disease is non-small cell lung carcinoma.